Skip to content
drillr.ai
Sign up

AVR

Anteris Technologies Global Corp.

NASDAQ · Healthcare · Medical - Devices · AU

$9.04
+3.67%
Ask drillr

  • Aug 12, 2026, 00:00 UTC

    Anteris Technologies Global Corp. reported its Q2 2026 financial results, with H1 2026 revenues of $1.503 million, up 28% year-over-year, and a net loss after tax of $51.675 million for H1 2026.

  • Aug 11, 2026, 08:09 UTC

    L1 Capital Pty Ltd, a major shareholder of Anteris Technologies Global Corp., sold 174,721 shares of the company's stock on August 6, 2026, at an average price of $8.10, totaling $1,415,240.10.

    Source:

  • Jun 8, 2026, 10:00 UTC

    Anteris Technologies Global Corp. received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for its DurAVR Transcatheter Heart Valve global pivotal trial (PARADIGM Trial).